Hansoh Pharmaceutical Group CoHNSPF 91 Return-on-Tangible-Equity is 14.85% as of Dec. 2025, which is 15% below its 10-year median of 17.43. GuruFocus rates HNSPF with a GF Score™ of 91/100 and a GF Value™ of $3.64 (Fairly Valued). Among 897 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks better than 75.7% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hansoh Pharmaceutical Group Co's annualized net income for the quarter that ended in Dec. 2025 was $687 Mil. Hansoh Pharmaceutical Group Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $4,630 Mil. Therefore, Hansoh Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 14.85%.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's Return-on-Tangible-Equity or its related term are showing as below:
HNSPF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.6 Med: 17.43 Max: 55.16
Current: 17.82
During the past 10 years, Hansoh Pharmaceutical Group Co's highest Return-on-Tangible-Equity was 55.16%. The lowest was 11.60%. And the median was 17.43%.
HNSPF's Return-on-Tangible-Equity is ranked better than 75.7% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs HNSPF: 17.82
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Hansoh Pharmaceutical Group Co Return-on-Tangible-Equity Related Terms
Hansoh Pharmaceutical Group Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co Return-on-Tangible-Equity Chart
HNSPF vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.85% mean?
Hansoh Pharmaceutical Group Co (HNSPF) has a Return-on-Tangible-Equity of 14.85% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 15% below median its historical median of 17.43. Over the past decade, Hansoh Pharmaceutical Group Co's Return-on-Tangible-Equity has ranged from 11.60 to 55.16. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #218 out of 897 companies in the Drug Manufacturers industry, placing it in the top 24.3%.
Is Hansoh Pharmaceutical Group Co's Return-on-Tangible-Equity too high?
Hansoh Pharmaceutical Group Co's current Return-on-Tangible-Equity of 14.85% is 15% below median its 10-year median of 17.43. Over the past 10 years, this metric has ranged from a low of 11.60 to a high of 55.16. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Hansoh Pharmaceutical Group Co's value of 14.85% is 88% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #218 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #218 out of 897 companies for Return-on-Tangible-Equity. This places Hansoh Pharmaceutical Group Co in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Hansoh Pharmaceutical Group Co's value of 14.85% is 88% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own Return-on-Tangible-Equity has ranged from 11.60 to 55.16 over the past decade. While the company's 10-year median is 17.43 vs. the industry median of 7.90, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current Return-on-Tangible-Equity of 14.85% is 88% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current Return-on-Tangible-Equity is 14.85%, which is 15% below median its own 10-year median of 17.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Fairly Valued. The stock's GF Value™ is $3.64, compared to a current price of $3.83 — trading 5.1% above its estimated fair value. The current Return-on-Tangible-Equity is 14.85%, which is 15% below median its 10-year median of 17.43 and 88% above the Drug Manufacturers industry median of 7.90. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current Return-on-Tangible-Equity is 14.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $3.83 is trading 5.1% above its estimated GF Value™ of $3.64.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for HNSPF:
Return-on-Tangible-Equity: 14.85% (15% below median its 10-year median of 17.43)
GF Value™: $3.64 vs. price of $3.83 (5.1% above fair value)
Industry Position: 88% above the Drug Manufacturers median (#218 of 897)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Business Description
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score
Get the complete analysis for HNSPF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
